Search Results

You are looking at 21 - 30 of 41 items for :

  • "pamidronate" x
  • All content x
Clear All
Full access

William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice Lyons, P. Kelly Marcom, Jennifer Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar

compression, and hypercalcemia of malignancy. The NCCN panel recommends treatment with a bone-modifying agent such as zoledronic acid, pamidronate, or denosumab (category 1) in addition to chemotherapy or endocrine therapy if bone metastasis is present

Full access

Shaji K. Kumar, Natalie S. Callander, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Matthew Faiman, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Michaela Liedtke, Thomas Martin, James Omel, Noopur Raje, Frederic J. Reu, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead, and Rashmi Kumar

monthly use of intravenous pamidronate (a bisphosphonate) can decrease pain and bone-related complications, improve performance status, and, importantly, preserve quality of life in patients with Durie-Salmon stage III MM and at least one lytic lesion. 163

Full access

Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Seema Singhal, Clayton Smith, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead, and Rashmi Kumar

( P =.9). Attal et al 173 randomized 597 patients to one of three different strategies after tandem autologous SCT: no maintenance, pamidronate alone, or pamidronate combined with thalidomide.There was a highly significant EFS and OS advantage in the

Full access

Rashmi Chugh

, and potentially a direct tumor effect. 29 , 32 In vitro data suggest that bisphosphonates can inhibit growth and proliferation in osteosarcoma cell lines. 33 – 36 Preliminary results of a phase II study of pamidronate and standard chemotherapy in

Full access

Charise Gleason, Ajay Nooka, and Sagar Lonial

Lichtenstein A Porter L . Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group . N Engl J Med 1996 ; 334 : 488 – 493 . 47 Berenson JR Rosen LS Howell A . Zoledronic acid

Full access

health in patients, including surgical options and bisphosphonates. She provided an overview of clinical trial data showing the equivalence of pamidronate versus zoledronic acid, discussed data showing the survival advantage with zoledronic acid compared

Full access

Matthew Mei and George Somlo

randomizing patients to placebo, pamidronate, or the combination thalidomide and pamidronate as maintenance therapy post-ASCT showed improved EFS and OS in the combination arm. 29 However, post-ASCT thalidomide was not found to improve OS and conferred

Full access

Ruben Niesvizky and Ashraf Z. Badros

guidelines have been established for the use of pamidronate in patients with severe renal failure; however, ASCO recommends a reduced dosage. 37 In general, bisphosphonates should be used with extreme caution in MM patients with renal impairment, and all MM

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff, and Richard Zellars

breast cancer in bone to prevent bone fractures, bone pain requiring radiation therapy, spinal cord compression, and hypercalcemia (skeletal related events [SREs]). 279 – 281 The bisphosphonates zoledronic acid or pamidronate have been used for this

Full access

Angel Qin, Songzhu Zhao, Abdul Miah, Lai Wei, Sandipkumar Patel, Andrew Johns, Madison Grogan, Erin M. Bertino, Kai He, Peter G. Shields, Gregory P. Kalemkerian, Shirish M. Gadgeel, Nithya Ramnath, Bryan J. Schneider, Khaled A. Hassan, Nicholas Szerlip, Zoey Chopra, Sara Journey, Jessica Waninger, Daniel Spakowicz, David P. Carbone, Carolyn J. Presley, Gregory A. Otterson, Michael D. Green, and Dwight H. Owen

, and an increased population of suppressive immune cells, such as regulatory T cells and myeloid-derived suppressor cells. 9 The FDA has approved the use of BMA, including bisphosphonates (pamidronate and zoledronic acid) and denosumab (a monoclonal